Over $1.4 billion! Novartis ‘steps up’ molecular glue

▤ Summary

Novartis has expanded its collaboration with Orionis Biosciences to develop molecular glue drugs across multiple difficult disease targets. The deal uses Orionis’ Allo-Glue platform and AI-driven discovery engine to speed target and ligase research and optimize molecular glue candidates. Orionis will receive $40 million upfront and could earn up to $1.4 billion in research, development, and commercialization milestones, plus tiered sales royalties. The partnership deepens an existing relationship that began in 2020 and follows earlier financing and collaboration activity with other major biopharma partners.

▦ Linked Companies